Heni Riyanto and Nurwasis and Rahardjo (2007) Penggunaan Brimonidin (Agois Alfa-2 Adrenergik) sebagai Terapi Glaukoma. Jurnal Oftalmologi Indonesia, 5 (1). pp. 27-39. ISSN 16932587

	Text (Artikel) Penggunaan Brimonidin (Agonis Alfa-2 Adrenergik) sebagai Terapi Glaukoma_compressed.pdf Download (5MB)
	Text (Peer Review) Penggunaan Brimonidin.pdf Download (1MB)
	Text (Similarity) Penggunaan Brimonidin (Agonis Alfa-2 Adrenergik) sebagai Terapi Glaukoma_compressed.pdf Download (3MB)

Abstract

Brimonidine is a highly selective alpha2-adrenoceptor agonist which reduces intraocular pressure (IOP) by reducing aqueous humor production and increasing aqueous humor outflow via the uveoscleral pathway. Brimonidine is indicated for the topical management of open-angle glaucoma or ocular hypertension. The reommended dose of brimonidine 0,2% is one drop in the affected eye two or three times daily, approximately three hours apart. A dose-response effect was observed after single dose administration of brimonidine to pattients with glaucoma or ocular hypertension; IOP reductions from baseline of 16,1, 22,4 and 30,1% were achieved after administration of brimonidine 0,08, 0,2 or 005%, respectively. The most frequent adverse events associated with brimonidine therapy were oral dryness (30,0%), ocular hyperaemia (26,3%) and ocular burning and/or stinging (24,0%). Brimonidine may have the potential additional benefit of providing neuroprotection for glaucoma patients. Studies have already demonstrated that brimonidine meets 3 of the 4 criterian used in evaluating neuroprotective agents, and clinical trials are in progress to determine whether brimonidine also fulfills the last criterian and is there neuroprotective effect in human eyes.

Actions (login required)

View Item